Article Details
Retrieved on: 2021-07-23 11:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NGM Biopharma Completes Enrollment Into Phase 2 Study of NGM621 In Geographic Atrophy. NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) said it ...
Article found on: markets.businessinsider.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here